Special Drug Use-results Survey for long-term use of Trelief 50mg/day (TOMORROW-PD)

Special Drug Use-results Survey for long-term use of Trelief 50mg/day (TOMORROW-PD) - TOMORROW-PD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016370

Enrollment

500

Registered

2015-01-31

Start date

2015-02-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the following criteria at the start of Trelief 50mg/day treatment are eligible for the survey. 1. Patients with Parkinson's disease and "wearing-off" symptoms. 2. Patients from whom informed consent to publish this survey result are obtained. 3. Patients whose clinical symptom score, wearing-off period, and EQ-5D are all evaluated.

Exclusion criteria

Exclusion criteria: Patients who had previously received zonisamide, except for cases switching from Trelief 25mg/day treatment to 50mg/day treatment.

Design outcomes

Primary

Measure	Time frame
Safety; Adverse Event Efficacy; Overall improvement, Clinical symptom score, Wearing-off period, EQ-5D	—

Countries

Japan

Contacts

Public ContactShunsuke Tani

Sumitomo Dainippon Pharma Co.,Ltd. Pharmacovigilance Department

shunsuke-tani@ds-pharma.co.jp06-6203-6419

Outcome results